Webinar: Novel Applications of the Cellular Thermal Shift Assay (CETSA) Provide New Insights for Drug Discovery by InsideScientific

How did the webinar compare to your expectations?

Excellent

Good

Average

Poor

Novel Applications of the Cellular Thermal Shift Assay (CETSA) Provide New Insights for Drug Discovery

About

Join AbbVie scientists Shitalben Patel and Jami R. Erickson as they showcase their innovative advancements, transforming CETSA® into a high-throughput flow-based platform and introducing new whole blood formats to elevate drug discovery.

In this webinar, you’ll learn about flow-based CETSA, a powerful, high-throughput technique that enables single-cell target engagement analysis without cell lysis. Designed for screening of large compound libraries, this method overcomes traditional limitations like low throughput and high cell input. You will also hear how the method is being integrated into real-world SAR funnels to accelerate hit generation.

In the second half of the webinar, you will learn about novel Alpha and MSD CETSA formats for whole blood, using RIPK1 as a proof-of-concept. These assays require <100 μL of blood, eliminate PBMC isolation, and deliver clinically relevant, reproducible readouts—bringing true target engagement measurement closer to patient-derived samples.

Don’t miss this opportunity to explore how these CETSA innovations can transform your approach to drug discovery—from high-throughput screening to clinical translation.

Key Topics:

High-Throughput CETSA Innovation: Learn about the flow-based adaptation of CETSA, enabling rapid, large-scale compound screening using 384-well plates.

Flow Cytometry-Based Methodology: Discover how this technique detects thermostabilized proteins without cell lysis, allowing detailed single-cell analysis.

Application in Drug Discovery: See how flow-based CETSA integrates into SAR funnels, accelerating hit generation for endogenous targets in native cells.

Whole Blood CETSA Development: Explore two novel formats—Alpha CETSA and MSD CETSA—that use <100 μL blood and eliminate PBMC isolation.

Clinical Relevance: These blood-based assays enable direct, scalable target engagement readouts and support asynchronous, centralized clinical workflows

Translational Potential: Together, these innovations bridge preclinical research and clinical application, streamlining drug development in native biological systems.

All intellectual property rights, including copyrights and trademarks, relating to CETSA are owned by Pelago Bioscience AB.

Presenters

Shitalben Patel, MSc

Scientist, Chemical Biology and Mass Spectrometry Technology, Discovery Research, AbbVie

Shitalben Patel is a Scientist in the chemical biology group at AbbVie. Her role involves developing high-throughput chemoproteomics workflows, employing chemical biology technologies to understand drug-target engagement, on and off-target selectivity profiling, as well as mechanism-of-action for small molecule drug discovery. She received her Master of Science in Applied Biology from the Missouri University of Science and Technology before joining the Department of Pharmacy Practice at the University of Illinois at Chicago as a Research Scientist for 15 years, where she focused on translational research in pharmacogenomics and pharmacokinetics.

Jami R. Erickson, PhD

Senior Scientist, Molecular Screening and Characterization, Discovery Research, AbbVie

Dr. Jami R. Erickson is a Senior Scientist in the molecular screening and characterization group at AbbVie in North Chicago. Her work focuses on high-throughput screening and innovative technique development, including the pioneering of flow-based CETSA techniques. Dr. Erickson earned her Ph.D. in Molecular, Cellular, Developmental Biology, and Genetics from the University of Minnesota, where she conducted her thesis research on regenerative medicine in Dr. Karen Echeverri's laboratory. She later completed her postdoctoral studies at the Fred Hutchinson Cancer Research Center in Dr. Martin Prlic's laboratory, utilizing scRNAseq to investigate the human immune response to cancer and viruses.

First Name*

Last Name*

Email Address*

Country / Region*

Job Title*

Organization / Company*

Organization Type*

Your Therapeutic Area(s)*

utm_bmcr_source